Yonsei Med J.  2019 Nov;60(11):1061-1066. 10.3349/ymj.2019.60.11.1061.

Implementation of a Targeted Next-Generation Sequencing Panel for Constitutional Newborn Screening in High-Risk Neonates

• Lee H
• Lim J
• Shin JE
• Eun HS
• Park MS
• Park KI
• Namgung R
• Lee JS

• KMID: 2460223
• DOI: http://doi.org/10.3349/ymj.2019.60.11.1061

Abstract

PURPOSE
Newborn screening (NBS) programs are important for appropriate management of susceptible neonates to prevent serious clinical problems. Neonates admitted to neonatal intensive care units (NICU) are at a potentially high risk of false-positive results, and repetitive NBS after total parenteral nutrition is completely off results in delayed diagnosis. Here, we present the usefulness of a targeted next-generation sequencing (TNGS) panel to complement NBS for early diagnosis in high-risk neonates.
MATERIALS AND METHODS
The TNGS panel covered 198 genes associated with actionable genetic and metabolic diseases that are typically included in NBS programs in Korea using tandem mass spectrometry. The panel was applied to 48 infants admitted to the NICU of Severance Children's Hospital between May 2017 and September 2017. The infants were not selected for suspected metabolic disorders.
RESULTS
A total of 13 variants classified as likely pathogenic or pathogenic were detected in 11 (22.9%) neonates, including six genes (DHCR7, PCBD1, GAA, ALDOB, ATP7B, and GBA) associated with metabolic diseases not covered in NBS. One of the 48 infants was diagnosed with an isobutyl-CoA dehydrogenase deficiency, and false positive results of tandem mass screening were confirmed in two infants using the TNGS panel.
CONCLUSION
The implementation of TNGS in conjunction with conventional NBS can allow for better management of and earlier diagnosis in susceptible infants, thus preventing the development of critical conditions in these sick infants.

Keyword

Newborn screening; targeted next-generation sequencing; stressed infants; NBS; false-positive results; inborn errors of metabolism

MeSH Terms

Complement System Proteins
Delayed Diagnosis
Diagnosis
Early Diagnosis
Humans
Infant
Infant, Newborn*
Intensive Care Units, Neonatal
Korea
Mass Screening*
Metabolic Diseases
Metabolism, Inborn Errors
Oxidoreductases
Parenteral Nutrition, Total
Tandem Mass Spectrometry
Complement System Proteins
Oxidoreductases

Reference

1. Berry SA. Newborn screening. Clin Perinatol. 2015; 42:441–453. PMID: 26042913.

2. Therrell BL, Padilla CD, Loeber JG, Kneisser I, Saadallah A, Borrajo GJ, et al. Current status of newborn screening worldwide: 2015. Semin Perinatol. 2015; 39:171–187. PMID: 25979780.

3. Bhattacharjee A, Sokolsky T, Wyman SK, Reese MG, Puffenberger E, Strauss K, et al. Development of DNA confirmatory and high-risk diagnostic testing for newborns using targeted next-generation DNA sequencing. Genet Med. 2015; 17:337–347. PMID: 25255367.

4. Bodian DL, Klein E, Iyer RK, Wong WS, Kothiyal P, Stauffer D, et al. Utility of whole-genome sequencing for detection of newborn screening disorders in a population cohort of 1,696 neonates. Genet Med. 2016; 18:221–230. PMID: 26334177.

5. Miller J, Tuerck J, Awad K, Chace DH, Copeland S, Rasmussen SA, et al. Newborn screening for preterm, low birth weight, and sick newborns; approved guideline. CLSI document I/LA31-A. 1st ed. Wayne (PA): Clinical and Laboratory Standards Institute;2009.

6. Morris M, Fischer K, Leydiker K, Elliott L, Newby J, Abdenur JE. Reduction in newborn screening metabolic false-positive results following a new collection protocol. Genet Med. 2014; 16:477–483. PMID: 24177054.

7. Saunders CJ, Miller NA, Soden SE, Dinwiddie DL, Noll A, Alnadi NA, et al. Rapid whole-genome sequencing for genetic disease diagnosis in neonatal intensive care units. Sci Transl Med. 2012; 4:154ra135.

8. Lalani SR. Current genetic testing tools in Neonatal Medicine. Pediatr Neonatol. 2017; 58:111–121. PMID: 28277305.

9. Holm IA, Agrawal PB, Ceyhan-Birsoy O, Christensen KD, Fayer S, Frankel LA, et al. The BabySeq project: implementing genomic sequencing in newborns. BMC Pediatr. 2018; 18:225. PMID: 29986673.

10. Ceyhan-Birsoy O, Murry JB, Machini K, Lebo MS, Yu TW, Fayer S, et al. Interpretation of genomic sequencing results in healthy and ill newborns: results from the BabySeq project. Am J Hum Genet. 2019; 104:76–93. PMID: 30609409.

11. Pereira S, Robinson JO, Gutierrez AM, Petersen DK, Hsu RL, Lee CH, et al. Perceived benefits, risks, and utility of newborn genomic sequencing in the BabySeq project. Pediatrics. 2019; 143(Suppl 1):S6–S13. PMID: 30600265.

12. Cho Y, Lee CH, Jeong EG, Kim MH, Hong JH, Ko Y, et al. Prevalence of rare genetic variations and their implications in NGS-data interpretation. Sci Rep. 2017; 7:9810. PMID: 28851938.

13. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015; 17:405–424. PMID: 25741868.

14. Choi JH, Jin HY, Lee BH, Ko JM, Lee JJ, Kim GH, et al. Clinical phenotype and mutation spectrum of the CYP21A2 gene in patients with steroid 21-hydroxylase deficiency. Exp Clin Endocrinol Diabetes. 2012; 120:23–27. PMID: 22020670.

15. American College of Medical Genetics (ACMG), ACT. Sheets and confirmatory algorithms [Internet]. Bethesda: ACMG;c2001. accessed on 2019 April 1. Available at: https://www.ncbi.nlm.nih.gov/books/NBK55827/.

16. Daoud H, Luco SM, Li R, Bareke E, Beaulieu C, Jarinova O, et al. Next-generation sequencing for diagnosis of rare diseases in the neonatal intensive care unit. CMAJ. 2016; 188:E254–E260. PMID: 27241786.

17. Lim EC, Brett M, Lai AH, Lee SP, Tan ES, Jamuar SS, et al. Next-generation sequencing using a pre-designed gene panel for the molecular diagnosis of congenital disorders in pediatric patients. Hum Genomics. 2015; 9:33. PMID: 26666243.

18. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med. 2013; 15:565–574. PMID: 23788249.

19. Lawrence L, Sincan M, Markello T, Adams DR, Gill F, Godfrey R, et al. The implications of familial incidental findings from exome sequencing: the NIH Undiagnosed Diseases Program experience. Genet Med. 2014; 16:741–750. PMID: 24784157.